Future directions for GFAP as a biomarker in MS should therefore emphasize its integration into multimodal biomarker panels combining parameters of axonal damage (e.g., NfL), neuroinflammation, and astrocytic activation. This evidence concerns the gene GFAP and myeloid sarcoma.